JP2013506675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506675A5 JP2013506675A5 JP2012532248A JP2012532248A JP2013506675A5 JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5 JP 2012532248 A JP2012532248 A JP 2012532248A JP 2012532248 A JP2012532248 A JP 2012532248A JP 2013506675 A5 JP2013506675 A5 JP 2013506675A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- notch3
- notch1
- antagonist
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24729809P | 2009-09-30 | 2009-09-30 | |
| US61/247,298 | 2009-09-30 | ||
| PCT/US2010/050610 WO2011041336A2 (en) | 2009-09-30 | 2010-09-29 | Methods of treating cancer using notch antagonists |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011573A Division JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Division JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506675A JP2013506675A (ja) | 2013-02-28 |
| JP2013506675A5 true JP2013506675A5 (enExample) | 2013-10-17 |
| JP6025563B2 JP6025563B2 (ja) | 2016-11-16 |
Family
ID=43127684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532248A Active JP6025563B2 (ja) | 2009-09-30 | 2010-09-29 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療 |
| JP2015011573A Withdrawn JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Pending JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015011573A Withdrawn JP2015145362A (ja) | 2009-09-30 | 2015-01-23 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
| JP2016138236A Pending JP2017014219A (ja) | 2009-09-30 | 2016-07-13 | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9200071B2 (enExample) |
| EP (1) | EP2483311B1 (enExample) |
| JP (3) | JP6025563B2 (enExample) |
| KR (1) | KR101782180B1 (enExample) |
| CN (1) | CN102630229B (enExample) |
| AU (1) | AU2010300747A1 (enExample) |
| BR (1) | BR112012007252A2 (enExample) |
| CA (1) | CA2775880A1 (enExample) |
| CL (1) | CL2012000800A1 (enExample) |
| CO (1) | CO6531430A2 (enExample) |
| CR (1) | CR20120213A (enExample) |
| EC (1) | ECSP12011858A (enExample) |
| ES (1) | ES2580229T3 (enExample) |
| IL (1) | IL218662A0 (enExample) |
| MA (1) | MA33973B1 (enExample) |
| MX (1) | MX342250B (enExample) |
| PE (1) | PE20120998A1 (enExample) |
| PH (1) | PH12012500574A1 (enExample) |
| RU (1) | RU2012117619A (enExample) |
| WO (1) | WO2011041336A2 (enExample) |
| ZA (1) | ZA201201984B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2133796C1 (ru) * | 1997-10-09 | 1999-07-27 | ОАО "Томский электромеханический завод им.В.В.Вахрушева" | Люк смотрового колодца |
| PL2032166T3 (pl) | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| EP2307051B1 (en) | 2008-07-08 | 2015-02-11 | OncoMed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| PE20121494A1 (es) | 2009-06-18 | 2012-11-01 | Pfizer | Anticuerpos anti notch-1 |
| MX346995B (es) | 2010-12-15 | 2017-04-06 | Wyeth Llc | Anticuerpos anti-notch1. |
| KR20150082548A (ko) * | 2012-11-07 | 2015-07-15 | 화이자 인코포레이티드 | 항-notch3 항체 및 항체-약물 접합체 |
| WO2014100435A1 (en) * | 2012-12-19 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibodies |
| WO2014159242A1 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
| CN105246916A (zh) * | 2013-03-14 | 2016-01-13 | 诺华股份有限公司 | 针对notch 3的抗体 |
| CA2900969A1 (en) * | 2013-03-15 | 2014-09-25 | Oncomed Pharmaceuticals, Inc. | Methods of treating pancreatic cancer |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| WO2015123325A1 (en) | 2014-02-12 | 2015-08-20 | Genentech, Inc. | Anti-jagged1 antibodies and methods of use |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
| US11142573B2 (en) | 2016-04-29 | 2021-10-12 | Aveo Pharmaceuticals, Inc. | Anti-Notch3 antibody |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| CN101120021A (zh) | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| CL2007002987A1 (es) | 2006-10-19 | 2008-06-06 | Genentech Inc | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3. |
| CL2007002989A1 (es) * | 2006-10-19 | 2008-05-16 | Genentech Inc | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. |
| NZ577274A (en) | 2006-12-18 | 2012-10-26 | Genentech Inc | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| US8088617B2 (en) * | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
| EP2134356A2 (en) | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| EP2307051B1 (en) * | 2008-07-08 | 2015-02-11 | OncoMed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| PE20121494A1 (es) * | 2009-06-18 | 2012-11-01 | Pfizer | Anticuerpos anti notch-1 |
-
2010
- 2010-09-29 CA CA2775880A patent/CA2775880A1/en not_active Abandoned
- 2010-09-29 ES ES10762827.3T patent/ES2580229T3/es active Active
- 2010-09-29 AU AU2010300747A patent/AU2010300747A1/en not_active Abandoned
- 2010-09-29 KR KR1020127010886A patent/KR101782180B1/ko not_active Expired - Fee Related
- 2010-09-29 JP JP2012532248A patent/JP6025563B2/ja active Active
- 2010-09-29 WO PCT/US2010/050610 patent/WO2011041336A2/en not_active Ceased
- 2010-09-29 US US13/498,560 patent/US9200071B2/en active Active
- 2010-09-29 PE PE2012000413A patent/PE20120998A1/es not_active Application Discontinuation
- 2010-09-29 CN CN201080054108.9A patent/CN102630229B/zh active Active
- 2010-09-29 MA MA34797A patent/MA33973B1/fr unknown
- 2010-09-29 EP EP10762827.3A patent/EP2483311B1/en active Active
- 2010-09-29 PH PH1/2012/500574A patent/PH12012500574A1/en unknown
- 2010-09-29 BR BR112012007252-8A patent/BR112012007252A2/pt not_active IP Right Cessation
- 2010-09-29 RU RU2012117619/10A patent/RU2012117619A/ru not_active Application Discontinuation
- 2010-09-29 MX MX2012003851A patent/MX342250B/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218662A patent/IL218662A0/en unknown
- 2012-03-16 ZA ZA2012/01984A patent/ZA201201984B/en unknown
- 2012-03-30 CL CL2012000800A patent/CL2012000800A1/es unknown
- 2012-04-09 CO CO12057624A patent/CO6531430A2/es not_active Application Discontinuation
- 2012-04-26 CR CR20120213A patent/CR20120213A/es unknown
- 2012-04-30 EC ECSP12011858 patent/ECSP12011858A/es unknown
-
2015
- 2015-01-23 JP JP2015011573A patent/JP2015145362A/ja not_active Withdrawn
-
2016
- 2016-07-13 JP JP2016138236A patent/JP2017014219A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506675A5 (enExample) | ||
| RU2012117619A (ru) | ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ, УСТОЙЧИВЫХ К ДЕЙСТВИЮ АНТАГОНИСТА Notch1, С ПОМОЩЬЮ АНТАГОНИСТА Notch3 | |
| EA033072B1 (ru) | Применение антител к семафорину 4d для лечения болезни хантингтона | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2015533788A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| WO2014037588A3 (en) | Methods and compounds for preventing, treating and diagnosing an inflammatory condition | |
| RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
| JP2013198490A5 (enExample) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2017535257A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2013542194A5 (enExample) | ||
| NZ611269A (en) | Neutralizing anti-ccl20 antibodies | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2013538057A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2015511962A5 (enExample) | ||
| NZ630433A (en) | Antibodies and uses thereof to detect folate receptor 1 |